Tokyo-based Otsuka Pharmaceutical Co. Ltd. is taking its first step into the world of biologics with a $430 million all-cash acquisition offer for Visterra Inc., a company offering an antibody design and engineering platform that President and Director Tatsuo Higuchi said would provide it with "a powerful new drug creation engine."